1	4	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Discussion	_	_	NN	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	exposure	_	_	NN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	ERAV	_	_	NNP	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	as	_	_	IN	_	_	_	_	_
10	determined	_	_	VBN	_	_	_	_	_
11	by	_	_	IN	_	_	_	_	_
12	serological	_	_	JJ	_	_	_	_	_
13	testing	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	was	_	_	VBD	_	_	_	_	_
16	associated	_	_	VBN	_	_	_	_	_
17	with	_	_	IN	_	_	_	_	_
18	respiratory	_	_	JJ	_	_	_	_	_
19	disease	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	loss	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	training	_	_	NN	_	_	_	_	_
24	days	_	_	NNS	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	failure	_	_	NN	_	_	_	_	_
27	to	_	_	TO	_	_	_	_	_
28	race	_	_	VB	_	_	_	_	_
29	in	_	_	IN	_	_	_	_	_
30	young	_	_	JJ	_	_	_	_	_
31	racehorses	_	_	NNS	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	Monthly	_	_	JJ	_	_	_	_	_
2	screening	_	_	NN	_	_	_	_	_
3	indicated	_	_	VBD	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	majority	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	two-year-old	_	_	JJ	_	_	_	_	_
9	horses	_	_	NNS	_	_	_	_	_
10	were	_	_	VBD	_	_	_	_	_
11	exposed	_	_	VBN	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	ERAV	_	_	NNP	_	_	_	_	_
14	during	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	three	_	_	CD	_	_	_	_	_
17	months	_	_	NNS	_	_	_	_	_
18	after	_	_	IN	_	_	_	_	_
19	entering	_	_	VBG	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	yard	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	clinical	_	_	JJ	_	_	_	_	_
3	signs	_	_	NNS	_	_	_	_	_
4	that	_	_	WDT	_	_	_	_	_
5	resulted	_	_	VBD	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	an	_	_	DT	_	_	_	_	_
8	interruption	_	_	NN	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	training	_	_	NN	_	_	_	_	_
11	were	_	_	VBD	_	_	_	_	_
12	primarily	_	_	RB	_	_	_	_	_
13	observed	_	_	VBN	_	_	_	_	_
14	after	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	horses	_	_	NNS	_	_	_	_	_
17	had	_	_	VBD	_	_	_	_	_
18	been	_	_	VBN	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	yard	_	_	NN	_	_	_	_	_
22	for	_	_	IN	_	_	_	_	_
23	several	_	_	JJ	_	_	_	_	_
24	weeks	_	_	NNS	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	were	_	_	VBD	_	_	_	_	_
27	being	_	_	VBG	_	_	_	_	_
28	prepared	_	_	VBN	_	_	_	_	_
29	for	_	_	IN	_	_	_	_	_
30	their	_	_	PRP$	_	_	_	_	_
31	first	_	_	JJ	_	_	_	_	_
32	race	_	_	NN	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	susceptibility	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	young	_	_	JJ	_	_	_	_	_
5	horses	_	_	NNS	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	rhinitis	_	_	NN	_	_	_	_	_
8	virus	_	_	NN	_	_	_	_	_
9	infection	_	_	NN	_	_	_	_	_
10	when	_	_	WRB	_	_	_	_	_
11	moved	_	_	VBN	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	new	_	_	JJ	_	_	_	_	_
15	environment	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	starting	_	_	VBG	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	comingle	_	_	VBG	_	_	_	_	_
20	with	_	_	IN	_	_	_	_	_
21	other	_	_	JJ	_	_	_	_	_
22	horses	_	_	NNS	_	_	_	_	_
23	has	_	_	VBZ	_	_	_	_	_
24	been	_	_	VBN	_	_	_	_	_
25	reported	_	_	VBN	_	_	_	_	_
26	previously	_	_	RB	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	a	_	_	DT	_	_	_	_	_
3	seven-year	_	_	JJ	_	_	_	_	_
4	serological	_	_	JJ	_	_	_	_	_
5	study	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	racehorses	_	_	NNS	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	Japan	_	_	NNP	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	69	_	_	CD	_	_	_	_	_
12	%	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	horses	_	_	NNS	_	_	_	_	_
15	that	_	_	WDT	_	_	_	_	_
16	seroconverted	_	_	VBD	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	ERAV	_	_	NNP	_	_	_	_	_
19	were	_	_	VBD	_	_	_	_	_
20	two	_	_	CD	_	_	_	_	_
21	years	_	_	NNS	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	age	_	_	NN	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	Black	_	_	NNP	_	_	_	_	_
26	et	_	_	FW	_	_	_	_	_
27	al.	_	_	FW	_	_	_	_	_
28	reported	_	_	VBD	_	_	_	_	_
29	that	_	_	IN	_	_	_	_	_
30	43	_	_	CD	_	_	_	_	_
31	%	_	_	NN	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	horses	_	_	NNS	_	_	_	_	_
34	seroconverted	_	_	VBD	_	_	_	_	_
35	to	_	_	TO	_	_	_	_	_
36	ERAV	_	_	NNP	_	_	_	_	_
37	within	_	_	IN	_	_	_	_	_
38	7	_	_	CD	_	_	_	_	_
39	months	_	_	NNS	_	_	_	_	_
40	of	_	_	IN	_	_	_	_	_
41	entering	_	_	VBG	_	_	_	_	_
42	a	_	_	DT	_	_	_	_	_
43	training	_	_	NN	_	_	_	_	_
44	stable	_	_	NN	_	_	_	_	_
45	in	_	_	IN	_	_	_	_	_
46	Australia	_	_	NNP	_	_	_	_	_
47	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	previous	_	_	JJ	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	training	_	_	NN	_	_	_	_	_
7	yard	_	_	NN	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	Ireland	_	_	NNP	_	_	_	_	_
10	indicated	_	_	VBD	_	_	_	_	_
11	that	_	_	IN	_	_	_	_	_
12	ERAV	_	_	NNP	_	_	_	_	_
13	infection	_	_	NN	_	_	_	_	_
14	was	_	_	VBD	_	_	_	_	_
15	largely	_	_	RB	_	_	_	_	_
16	confined	_	_	VBN	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	two-year-old	_	_	JJ	_	_	_	_	_
19	horses	_	_	NNS	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	was	_	_	VBD	_	_	_	_	_
22	most	_	_	RBS	_	_	_	_	_
23	prevalent	_	_	JJ	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	late	_	_	JJ	_	_	_	_	_
26	winter	_	_	NN	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	spring	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	we	_	_	PRP	_	_	_	_	_
4	believe	_	_	VBP	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	this	_	_	DT	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	first	_	_	JJ	_	_	_	_	_
10	investigation	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	association	_	_	NN	_	_	_	_	_
14	between	_	_	IN	_	_	_	_	_
15	ERAV	_	_	NNP	_	_	_	_	_
16	infection	_	_	NN	_	_	_	_	_
17	with	_	_	IN	_	_	_	_	_
18	interrupted	_	_	VBN	_	_	_	_	_
19	training	_	_	NN	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	failure	_	_	NN	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	race	_	_	VB	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Over	_	_	IN	_	_	_	_	_
2	55	_	_	CD	_	_	_	_	_
3	%	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	two-year-olds	_	_	NNS	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	study	_	_	NN	_	_	_	_	_
10	seroconverted	_	_	VBD	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	ERAV	_	_	NNP	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	May	_	_	NNP	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	June	_	_	NNP	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	none	_	_	CD	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	them	_	_	PRP	_	_	_	_	_
21	raced	_	_	VBD	_	_	_	_	_
22	at	_	_	IN	_	_	_	_	_
23	that	_	_	DT	_	_	_	_	_
24	time	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	fact	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	only	_	_	RB	_	_	_	_	_
5	29	_	_	CD	_	_	_	_	_
6	%	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	two-year-olds	_	_	NNS	_	_	_	_	_
10	raced	_	_	VBD	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	their	_	_	PRP$	_	_	_	_	_
13	first	_	_	JJ	_	_	_	_	_
14	season	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	results	_	_	NNS	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	this	_	_	DT	_	_	_	_	_
5	study	_	_	NN	_	_	_	_	_
6	suggest	_	_	VBP	_	_	_	_	_
7	that	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	importance	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	ERAV	_	_	NN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	interruption	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	training	_	_	NN	_	_	_	_	_
17	programmes	_	_	NNS	_	_	_	_	_
18	for	_	_	IN	_	_	_	_	_
19	young	_	_	JJ	_	_	_	_	_
20	horses	_	_	NNS	_	_	_	_	_
21	may	_	_	MD	_	_	_	_	_
22	be	_	_	VB	_	_	_	_	_
23	underestimated	_	_	VBN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Acute	_	_	JJ	_	_	_	_	_
2	febrile	_	_	JJ	_	_	_	_	_
3	respiratory	_	_	JJ	_	_	_	_	_
4	disease	_	_	NN	_	_	_	_	_
5	following	_	_	VBG	_	_	_	_	_
6	ERAV	_	_	NNP	_	_	_	_	_
7	infection	_	_	NN	_	_	_	_	_
8	has	_	_	VBZ	_	_	_	_	_
9	been	_	_	VBN	_	_	_	_	_
10	reported	_	_	VBN	_	_	_	_	_
11	previously	_	_	RB	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	an	_	_	DT	_	_	_	_	_
3	experimental	_	_	JJ	_	_	_	_	_
4	study	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	ERAV-inoculated	_	_	JJ	_	_	_	_	_
7	ponies	_	_	NNS	_	_	_	_	_
8	developed	_	_	VBD	_	_	_	_	_
9	respiratory	_	_	JJ	_	_	_	_	_
10	tract	_	_	NN	_	_	_	_	_
11	disease	_	_	NN	_	_	_	_	_
12	characterized	_	_	VBN	_	_	_	_	_
13	by	_	_	IN	_	_	_	_	_
14	pyrexia	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	nasal	_	_	JJ	_	_	_	_	_
17	discharge	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	adventitious	_	_	JJ	_	_	_	_	_
20	lung	_	_	NN	_	_	_	_	_
21	sounds	_	_	NNS	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	enlarged	_	_	VBN	_	_	_	_	_
25	mandibular	_	_	JJ	_	_	_	_	_
26	lymph	_	_	NN	_	_	_	_	_
27	nodes	_	_	NNS	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	which	_	_	WDT	_	_	_	_	_
30	corresponded	_	_	VBD	_	_	_	_	_
31	with	_	_	IN	_	_	_	_	_
32	an	_	_	DT	_	_	_	_	_
33	increase	_	_	NN	_	_	_	_	_
34	in	_	_	IN	_	_	_	_	_
35	antibody	_	_	NN	_	_	_	_	_
36	titres	_	_	NNS	_	_	_	_	_
37	against	_	_	IN	_	_	_	_	_
38	the	_	_	DT	_	_	_	_	_
39	virus	_	_	NN	_	_	_	_	_
40	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	clinical	_	_	JJ	_	_	_	_	_
3	signs	_	_	NNS	_	_	_	_	_
4	observed	_	_	VBD	_	_	_	_	_
5	during	_	_	IN	_	_	_	_	_
6	this	_	_	DT	_	_	_	_	_
7	study	_	_	NN	_	_	_	_	_
8	were	_	_	VBD	_	_	_	_	_
9	associated	_	_	VBN	_	_	_	_	_
10	with	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	seroconversions	_	_	NNS	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	there	_	_	EX	_	_	_	_	_
15	was	_	_	VBD	_	_	_	_	_
16	no	_	_	DT	_	_	_	_	_
17	evidence	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	other	_	_	JJ	_	_	_	_	_
20	viral	_	_	JJ	_	_	_	_	_
21	infections	_	_	NNS	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	ERAV	_	_	NNP	_	_	_	_	_
2	may	_	_	MD	_	_	_	_	_
3	have	_	_	VB	_	_	_	_	_
4	been	_	_	VBN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	primary	_	_	JJ	_	_	_	_	_
7	cause	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	respiratory	_	_	JJ	_	_	_	_	_
11	disease	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	subsequent	_	_	JJ	_	_	_	_	_
14	training	_	_	NN	_	_	_	_	_
15	loss	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	but	_	_	CC	_	_	_	_	_
18	it	_	_	PRP	_	_	_	_	_
19	is	_	_	VBZ	_	_	_	_	_
20	more	_	_	RBR	_	_	_	_	_
21	likely	_	_	JJ	_	_	_	_	_
22	that	_	_	IN	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	virus	_	_	NN	_	_	_	_	_
25	was	_	_	VBD	_	_	_	_	_
26	a	_	_	DT	_	_	_	_	_
27	contributory	_	_	JJ	_	_	_	_	_
28	factor	_	_	NN	_	_	_	_	_
29	in	_	_	IN	_	_	_	_	_
30	a	_	_	DT	_	_	_	_	_
31	multifactorial	_	_	JJ	_	_	_	_	_
32	disorder	_	_	NN	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	serology	_	_	NN	_	_	_	_	_
3	tests	_	_	NNS	_	_	_	_	_
4	used	_	_	VBN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	this	_	_	DT	_	_	_	_	_
7	study	_	_	NN	_	_	_	_	_
8	are	_	_	VBP	_	_	_	_	_
9	sensitive	_	_	JJ	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	specific	_	_	JJ	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	but	_	_	CC	_	_	_	_	_
14	it	_	_	PRP	_	_	_	_	_
15	is	_	_	VBZ	_	_	_	_	_
16	possible	_	_	JJ	_	_	_	_	_
17	that	_	_	IN	_	_	_	_	_
18	other	_	_	JJ	_	_	_	_	_
19	less	_	_	RBR	_	_	_	_	_
20	common	_	_	JJ	_	_	_	_	_
21	viruses	_	_	NNS	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	such	_	_	JJ	_	_	_	_	_
24	as	_	_	IN	_	_	_	_	_
25	adenovirus	_	_	NN	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	coronavirus	_	_	NN	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	or	_	_	CC	_	_	_	_	_
30	even	_	_	RB	_	_	_	_	_
31	as-yet	_	_	JJ	_	_	_	_	_
32	unidentified	_	_	JJ	_	_	_	_	_
33	equine	_	_	JJ	_	_	_	_	_
34	viruses	_	_	NNS	_	_	_	_	_
35	,	_	_	,	_	_	_	_	_
36	may	_	_	MD	_	_	_	_	_
37	have	_	_	VB	_	_	_	_	_
38	played	_	_	VBN	_	_	_	_	_
39	a	_	_	DT	_	_	_	_	_
40	role	_	_	NN	_	_	_	_	_
41	.	_	_	.	_	_	_	_	_


1	Previous	_	_	JJ	_	_	_	_	_
2	studies	_	_	NNS	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	demonstrated	_	_	VBN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	complexity	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	poor	_	_	JJ	_	_	_	_	_
9	performance	_	_	NN	_	_	_	_	_
10	syndrome	_	_	NN	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	Thoroughbred	_	_	NNP	_	_	_	_	_
13	racehorses	_	_	NNS	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	that	_	_	IN	_	_	_	_	_
16	bacteria	_	_	NNS	_	_	_	_	_
17	are	_	_	VBP	_	_	_	_	_
18	more	_	_	RBR	_	_	_	_	_
19	common	_	_	JJ	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	may	_	_	MD	_	_	_	_	_
22	be	_	_	VB	_	_	_	_	_
23	aetiologically	_	_	RB	_	_	_	_	_
24	more	_	_	RBR	_	_	_	_	_
25	important	_	_	JJ	_	_	_	_	_
26	than	_	_	IN	_	_	_	_	_
27	viruses	_	_	NNS	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	Unfortunately	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	possible	_	_	JJ	_	_	_	_	_
5	role	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	bacterial	_	_	JJ	_	_	_	_	_
8	infection	_	_	NN	_	_	_	_	_
9	as	_	_	IN	_	_	_	_	_
10	a	_	_	DT	_	_	_	_	_
11	cofactor	_	_	NN	_	_	_	_	_
12	was	_	_	VBD	_	_	_	_	_
13	not	_	_	RB	_	_	_	_	_
14	investigated	_	_	VBN	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	this	_	_	DT	_	_	_	_	_
17	study	_	_	NN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	statistically	_	_	RB	_	_	_	_	_
21	significant	_	_	JJ	_	_	_	_	_
22	association	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	ERAV	_	_	NNP	_	_	_	_	_
25	with	_	_	IN	_	_	_	_	_
26	failure	_	_	NN	_	_	_	_	_
27	to	_	_	TO	_	_	_	_	_
28	race	_	_	VB	_	_	_	_	_
29	during	_	_	IN	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	study	_	_	NN	_	_	_	_	_
32	period	_	_	NN	_	_	_	_	_
33	does	_	_	VBZ	_	_	_	_	_
34	not	_	_	RB	_	_	_	_	_
35	conclusively	_	_	RB	_	_	_	_	_
36	demonstrate	_	_	VB	_	_	_	_	_
37	causation	_	_	NN	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	it	_	_	PRP	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	essential	_	_	JJ	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	determine	_	_	VB	_	_	_	_	_
8	which	_	_	WDT	_	_	_	_	_
9	infectious	_	_	JJ	_	_	_	_	_
10	agents	_	_	NNS	_	_	_	_	_
11	are	_	_	VBP	_	_	_	_	_
12	prevalent	_	_	JJ	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	populations	_	_	NNS	_	_	_	_	_
15	that	_	_	WDT	_	_	_	_	_
16	suffer	_	_	VBP	_	_	_	_	_
17	interruption	_	_	NN	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	training	_	_	NN	_	_	_	_	_
20	as	_	_	IN	_	_	_	_	_
21	a	_	_	DT	_	_	_	_	_
22	first	_	_	JJ	_	_	_	_	_
23	step	_	_	NN	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	assessing	_	_	VBG	_	_	_	_	_
26	their	_	_	PRP$	_	_	_	_	_
27	true	_	_	JJ	_	_	_	_	_
28	impact	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	Lack	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	previous	_	_	JJ	_	_	_	_	_
4	exposure	_	_	NN	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	ERAV	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	stress	_	_	NN	_	_	_	_	_
9	associated	_	_	VBN	_	_	_	_	_
10	with	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	change	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	environment	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	intensive	_	_	JJ	_	_	_	_	_
17	training	_	_	NN	_	_	_	_	_
18	may	_	_	MD	_	_	_	_	_
19	have	_	_	VB	_	_	_	_	_
20	contributed	_	_	VBN	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	disease	_	_	NN	_	_	_	_	_
23	susceptibility	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	contrast	_	_	NN	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	two-year-old	_	_	JJ	_	_	_	_	_
6	horses	_	_	NNS	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	no	_	_	DT	_	_	_	_	_
9	seroconversions	_	_	NNS	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	ERAV	_	_	NNP	_	_	_	_	_
12	were	_	_	VBD	_	_	_	_	_
13	observed	_	_	VBN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	three-year-old	_	_	JJ	_	_	_	_	_
17	horses	_	_	NNS	_	_	_	_	_
18	—	_	_	:	_	_	_	_	_
19	they	_	_	PRP	_	_	_	_	_
20	remained	_	_	VBD	_	_	_	_	_
21	free	_	_	JJ	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	any	_	_	DT	_	_	_	_	_
24	signs	_	_	NNS	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	respiratory	_	_	JJ	_	_	_	_	_
27	disease	_	_	NN	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	raced	_	_	VBD	_	_	_	_	_
30	successfully	_	_	RB	_	_	_	_	_
31	throughout	_	_	IN	_	_	_	_	_
32	the	_	_	DT	_	_	_	_	_
33	study	_	_	NN	_	_	_	_	_
34	period	_	_	NN	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	seroconversion	_	_	NN	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	ERAV	_	_	NNP	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	four-year-old	_	_	JJ	_	_	_	_	_
8	horse	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	reinfection	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	two	_	_	CD	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	younger	_	_	JJR	_	_	_	_	_
17	horses	_	_	NNS	_	_	_	_	_
18	were	_	_	VBD	_	_	_	_	_
19	not	_	_	RB	_	_	_	_	_
20	associated	_	_	VBN	_	_	_	_	_
21	with	_	_	IN	_	_	_	_	_
22	clinical	_	_	JJ	_	_	_	_	_
23	signs	_	_	NNS	_	_	_	_	_
24	or	_	_	CC	_	_	_	_	_
25	reduced	_	_	VBN	_	_	_	_	_
26	performance	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Experimental	_	_	JJ	_	_	_	_	_
2	studies	_	_	NNS	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	indicated	_	_	VBN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	ERAV	_	_	NNP	_	_	_	_	_
7	infection	_	_	NN	_	_	_	_	_
8	stimulated	_	_	VBD	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	protective	_	_	JJ	_	_	_	_	_
11	response	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	that	_	_	IN	_	_	_	_	_
14	reinfection	_	_	NN	_	_	_	_	_
15	is	_	_	VBZ	_	_	_	_	_
16	asymptomatic	_	_	JJ	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	serology	_	_	NN	_	_	_	_	_
3	results	_	_	NNS	_	_	_	_	_
4	indicate	_	_	VBP	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	ERAV	_	_	NNP	_	_	_	_	_
7	was	_	_	VBD	_	_	_	_	_
8	circulating	_	_	VBG	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	yard	_	_	NN	_	_	_	_	_
12	throughout	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	six	_	_	CD	_	_	_	_	_
15	month	_	_	NN	_	_	_	_	_
16	study	_	_	NN	_	_	_	_	_
17	period	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	dynamics	_	_	NNS	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	ERAV	_	_	NNP	_	_	_	_	_
5	infection	_	_	NN	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	horse	_	_	NN	_	_	_	_	_
8	populations	_	_	NNS	_	_	_	_	_
9	are	_	_	VBP	_	_	_	_	_
10	poorly	_	_	RB	_	_	_	_	_
11	understood	_	_	VBN	_	_	_	_	_
12	but	_	_	CC	_	_	_	_	_
13	virus	_	_	NN	_	_	_	_	_
14	persists	_	_	VBZ	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	horses	_	_	NNS	_	_	_	_	_
17	even	_	_	RB	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	presence	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	high	_	_	JJ	_	_	_	_	_
23	levels	_	_	NNS	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	antibodies	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	ERAV	_	_	NNP	_	_	_	_	_
2	can	_	_	MD	_	_	_	_	_
3	be	_	_	VB	_	_	_	_	_
4	isolated	_	_	VBN	_	_	_	_	_
5	from	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	blood	_	_	NN	_	_	_	_	_
8	for	_	_	IN	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	few	_	_	JJ	_	_	_	_	_
11	days	_	_	NNS	_	_	_	_	_
12	post	_	_	IN	_	_	_	_	_
13	infection	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	from	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	nasopharynx	_	_	NN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	faeces	_	_	NNS	_	_	_	_	_
20	for	_	_	IN	_	_	_	_	_
21	up	_	_	IN	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	a	_	_	DT	_	_	_	_	_
24	month	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Studies	_	_	NNS	_	_	_	_	_
2	in	_	_	IN	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	USA	_	_	NNP	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	Ireland	_	_	NNP	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	Australia	_	_	NNP	_	_	_	_	_
9	detected	_	_	VBD	_	_	_	_	_
10	ERAV	_	_	NNP	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	post-race	_	_	JJ	_	_	_	_	_
13	urine	_	_	NN	_	_	_	_	_
14	samples	_	_	NNS	_	_	_	_	_
15	at	_	_	IN	_	_	_	_	_
16	frequencies	_	_	NNS	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	17	_	_	CD	_	_	_	_	_
19	%	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	29	_	_	CD	_	_	_	_	_
22	%	_	_	NN	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	23	_	_	CD	_	_	_	_	_
25	%	_	_	NN	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	respectively	_	_	RB	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	which	_	_	WDT	_	_	_	_	_
30	led	_	_	VBD	_	_	_	_	_
31	to	_	_	TO	_	_	_	_	_
32	a	_	_	DT	_	_	_	_	_
33	suggestion	_	_	NN	_	_	_	_	_
34	that	_	_	IN	_	_	_	_	_
35	the	_	_	DT	_	_	_	_	_
36	persistent	_	_	JJ	_	_	_	_	_
37	presence	_	_	NN	_	_	_	_	_
38	of	_	_	IN	_	_	_	_	_
39	ERAV	_	_	NNP	_	_	_	_	_
40	in	_	_	IN	_	_	_	_	_
41	urine	_	_	NN	_	_	_	_	_
42	may	_	_	MD	_	_	_	_	_
43	contribute	_	_	VB	_	_	_	_	_
44	to	_	_	TO	_	_	_	_	_
45	its	_	_	PRP$	_	_	_	_	_
46	maintenance	_	_	NN	_	_	_	_	_
47	in	_	_	IN	_	_	_	_	_
48	training	_	_	NN	_	_	_	_	_
49	yards	_	_	NNS	_	_	_	_	_
50	.	_	_	.	_	_	_	_	_


1	ERBV	_	_	NNP	_	_	_	_	_
2	was	_	_	VBD	_	_	_	_	_
3	not	_	_	RB	_	_	_	_	_
4	detected	_	_	VBN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	urine	_	_	NN	_	_	_	_	_
7	.	_	_	.	_	_	_	_	_


1	During	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	period	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	only	_	_	RB	_	_	_	_	_
7	one	_	_	CD	_	_	_	_	_
8	horse	_	_	NN	_	_	_	_	_
9	seroconverted	_	_	VBD	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	ERBV	_	_	NNP	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	was	_	_	VBD	_	_	_	_	_
3	consistent	_	_	JJ	_	_	_	_	_
4	with	_	_	IN	_	_	_	_	_
5	an	_	_	DT	_	_	_	_	_
6	earlier	_	_	JJR	_	_	_	_	_
7	study	_	_	NN	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	Ireland	_	_	NNP	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	which	_	_	WDT	_	_	_	_	_
12	ERAV	_	_	NNP	_	_	_	_	_
13	was	_	_	VBD	_	_	_	_	_
14	found	_	_	VBN	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	be	_	_	VB	_	_	_	_	_
17	more	_	_	RBR	_	_	_	_	_
18	commonly	_	_	RB	_	_	_	_	_
19	detected	_	_	VBN	_	_	_	_	_
20	than	_	_	IN	_	_	_	_	_
21	ERBV	_	_	NNP	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Co-circulation	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	ERAV	_	_	NNP	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	ERBV	_	_	NNP	_	_	_	_	_
6	was	_	_	VBD	_	_	_	_	_
7	also	_	_	RB	_	_	_	_	_
8	reported	_	_	VBN	_	_	_	_	_
9	previously	_	_	RB	_	_	_	_	_
10	.	_	_	.	_	_	_	_	_

